Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations

August 16, 2018 By Law Offices of Thomas J. Lamb, P.A.

Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) such as Invokana, Jardiance, and Farxiga have a higher risk of leg, feet, and toe amputations drug-class side effect when compared to older diabetes drugs such as sulfonylureas, metformin, and thiazolidinediones. This finding was reported in the article “Association Between … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, Qtern, Segluromet, Steglatro, Steglujan, Synjardy, Xigduo

New SGLT2 Inhibitor Diabetes Drugs to Hit the Market in January

December 28, 2017 By Law Offices of Thomas J. Lamb, P.A.

Approval On December 19, 2017, the FDA approved Merck & Co. and Pfizer's new diabetes drug, Steglatro, and its two combination versions, Steglujan and Segluromet.  These drugs are classified as sodium/glucose cotransporter 2 (SGLT2) inhibitors, and will be available this coming January. Steglatro consists of ertugliflozin, while Steglujan … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs side effects, drug safety news, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, merck, new sglt2 inhibitors diabetes drugs, pfizer, Qtern, Segluromet, sglt2 inhibitors diabetes drugs, Steglatro, Steglujan, Synjardy, type 2 diabetes drugs, Xigduo

Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain

December 4, 2017 By Law Offices of Thomas J. Lamb, P.A.

It appears there needs to more medical research done on the risk of lower limb amputations for patients who use the increasing popular diabetes medicines in the sodium glucose cotransporter 2 (SGLT2) inhibitor class, such as canagliflozin (Invokana / Invokamet), empagliflozin (Jardiance / Glyxambi / Synjardy), and dapagliflozin (Farxiga / Xigduo / … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, Farxiga, Foot Amputation, Glyxambi, Invokamet, Invokana, Jardiance, Leg Amputation, lower limb amputations, Qtern, Synjardy, Toes Amputation

New Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance

November 13, 2017 By Law Offices of Thomas J. Lamb, P.A.

This article, “SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials”, was published in the October 2017 edition of Diabetologia. It presents the findings of medical researchers who conducted a systematic literature review to identify randomized controlled trials that reported … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Bladder Cancer, diabetes drugs, diabetes drugs side effects, Glyxambi, Jardiance, Sodium-Glucose-Cotransporter-2 Inhibitors, Synjardy, Synjardy XR

SGLT2 Inhibitors May Have an Increased Risk of Acute Renal Failure

October 31, 2017 By Law Offices of Thomas J. Lamb, P.A.

SGLT2 Inhibitors: A New Side Effect In previous articles, I have discussed SGLT2 inhibitor diabetes drugs such as Invokana, Farxiga, and Jardiance and the adverse events associated with them.  Such side effects include diabetic ketoacidosis (DKA) and lower-limb amputations. A recent study identified a new possible side effect of these drugs … [Read more...]

Filed Under: Unsafe Drugs Tagged With: acute renal failure, ARF, diabetes drugs, diabetes drugs renal failure, diabetes drugs side effects, FAERS, Farxiga, FDA Adverse Event Report System Database, Glyxambi, Invokamet, invokamet xr, Invokana, Jardiance, Qtern, sglt2 inhibitors, Sodium-Glucose-Cotransporter-2 Inhibitors, Synjardy, Synjardy XR, type 2 diabetes drugs, xigduo xr

Could Invokana have been the cause of my lower-limb amputation?

September 15, 2017 By Law Offices of Thomas J. Lamb, P.A.

The FDA is investigating a connection between diabetes drugs belonging to the Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors class of drugs and the following side effects: Diabetic Ketoacidosis (DKA) Ketoacidosis Ketosis Acute Kidney Injury Kidney Failure / Renal Failure Kidney Damage Pyelonephritis (kidney infection) … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Acute Kidney Injury, amputation risk factors, blood infection, diabetes drugs, diabetic ketoacidosis, DKA, drug injury lawsuits, Farxiga, Foot Amputation, Glyxambi, Invokamet, Invokana, Jardiance, Ketoacidosis, Ketosis, Kidney Damage, Kidney Failure, kidney infection, Leg Amputation, Pyelonephritis, Qtern, Renal Failure, sglt2 inhibitors, side effects of diabetes drugs, Sodium-Glucose Co-Transporter-2 inhibitors, Synjardy, Toes Amputation, Urinary Tract Infection, Urosepsis, UTI, Xigduo

Can SGLT-2 Inhibitor Diabetes Drugs Increase Your Risk of Stroke?

June 21, 2017 By Law Offices of Thomas J. Lamb, P.A.

While we have frequently discussed DKA, kidney damage, and amputations as possible side effects of diabetes drugs in the SGLT-2 inhibitors class -- such as Farxiga, Invokana, Jardiance -- strokes and thromboembolic events are also considered potential harmful effects of these drugs. Based on FAERS reports received during the second quarter of … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Acute Kidney Injury, Amputations, antidiabetic drugs, canagliflozin, canagliflozin/metformin HCl, causes of stroke, dapagliflozin, dapagliflozin/metformin HCl, Deep Vein Thrombosis, diabetes drugs, diabetic ketoacidosis, DKA, drug injury lawsuits, drug side effects, DVT, empagliflozin, empagliflozin/linagliptin, empagliflozin/metformin HCl, Farxiga, FDA, FDA FAERS reports, Glyxambi, Invokamet, Invokana, Jardiance, Kidney Damage, Kidney Failure, lower limb amputations, PE, Pulmonary Embolism, SGLT-2 inhibitors, Stroke, Synjardy, thromboembolic events, Xigduo, xigduo xr

Jardiance, Invokana, And Farxiga Double Risk Of Diabetic Ketoacidosis

June 14, 2017 By Law Offices of Thomas J. Lamb, P.A.

The June 8, 2017 edition of The New England Journal of Medicine (NEJM) has a “To the Editor” letter, titled “Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor”, which is likely causing some concerns among doctors and type 2 diabetes (T2D) patients. It is about the safety of Jardiance, Invokana, Farxiga, and other diabetes … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Diabetic Ketoacidosis (DKA), Farxiga, Glyxambi, Invokamet, Invokana, Qtern, Synjardy, Xigduo

Farxiga MDL Includes Diabetic Ketoacidosis And Kidney Damage Lawsuits

May 16, 2017 By Law Offices of Thomas J. Lamb, P.A.

On April 6, 2017 the United States Judicial Panel On Multidistrict Litigation (JPML) issued this document, “IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION TRANSFER ORDER — MDL No. 2776”, from which we get the following information: On the basis of the papers filed and the hearing session held, we find that these actions involve … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Diabetic Ketoacidosis (DKA), Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, Kidney Damage, Qtern, Synjardy, Xigduo

Farxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning

August 31, 2016 By Law Offices of Thomas J. Lamb, P.A.

In August 2016 the FDA sent letters to Janssen Pharmaceuticals and AstraZeneca Pharmaceuticals for label changes about fatal cases of ketoacidosis cases involving Invokana (canagliflozin), Invokamet (canagliflozin and metformin), Farxiga (dapagliflozin), and Xigduo XR (dapagliflozin and metformin extended-release). As for the other diabetes … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Acute Kidney Injury, Cerebral Vascular Accident (CVA), Deep Vein Thrombosis (DVT), Farxiga, Glyxambi, Heart Attacks, Invokamet, Invokana, Ischemic Stroke, Jardiance, Ketoacidosis, Kidney Damage, Kidney Failure, Myocardial Infarctions (MI), Pulmonary Embolism (PE), Pyelonephritis, Renal Failure, Synjardy, Urinary Tract Infection (UTI), Urosepsis, Xigduo

  • 1
  • 2
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.